NCT02077192Phase 3Completed

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Study sponsor: Rigel Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2020-06-02Actual
Enrollment · participants123Actual
Source updated2023-12-11Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview